Literature DB >> 11394741

Identification of cylin-dependent kinase 1 inhibitors of a new chemical type by structure-based design and database searching.

P Furet1, T Meyer, P Mittl, H Fretz.   

Abstract

We have selected cyclin-dependent kinase 1 (CDK1), an enzyme participating in the regulation of the cell cycle, as a target in our efforts to discover new antitumor agents. By exploiting available structural information, we designed an ATP-site directed ligand scaffold that allowed us to identify 4-(3-methyl-1,4-dioxo-1,4-dihydro-naphthalen-2-ylamino)-benzenesulfonamide as a new potent inhibitor of CDK1 in a subsequent database search. The synthesis and testing of some analogues confirmed the interest of this class of compounds as novel CDK1 inhibitors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11394741     DOI: 10.1023/a:1011128510728

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  19 in total

Review 1.  ATP-site directed inhibitors of cyclin-dependent kinases.

Authors:  N Gray; L Détivaud; C Doerig; L Meijer
Journal:  Curr Med Chem       Date:  1999-09       Impact factor: 4.530

2.  The cell cycle and drug discovery: the promise and the hope.

Authors: 
Journal:  Drug Discov Today       Date:  1999-10       Impact factor: 7.851

3.  Synthesis of substituted benzoquinones and naphthoquinones with potential antituberculous activity.

Authors:  I M Roushdi; A A Mikhail; I Chaaban
Journal:  Pharmazie       Date:  1977-05       Impact factor: 1.267

4.  Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms.

Authors:  A M Senderowicz; D Headlee; S F Stinson; R M Lush; N Kalil; L Villalba; K Hill; S M Steinberg; W D Figg; A Tompkins; S G Arbuck; E A Sausville
Journal:  J Clin Oncol       Date:  1998-09       Impact factor: 44.544

Review 5.  Cyclin-dependent kinases: engines, clocks, and microprocessors.

Authors:  D O Morgan
Journal:  Annu Rev Cell Dev Biol       Date:  1997       Impact factor: 13.827

6.  A new screening test for antimitotic compounds using the universal M phase-specific protein kinase, p34cdc2/cyclin Bcdc13, affinity-immobilized on p13suc1-coated microtitration plates.

Authors:  V Rialet; L Meijer
Journal:  Anticancer Res       Date:  1991 Jul-Aug       Impact factor: 2.480

7.  [Derivatives of 2-amino-1,4-naphthoquinone as carcinostatic agents].

Authors:  S Petersen; W Gauss; H Kiehne; L Jühling
Journal:  Z Krebsforsch       Date:  1969

8.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

Authors:  W F De Azevedo; H J Mueller-Dieckmann; U Schulze-Gahmen; P J Worland; E Sausville; S H Kim
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-02       Impact factor: 11.205

9.  Structure-based design of potent CDK1 inhibitors derived from olomoucine.

Authors:  P Furet; J Zimmermann; H G Capraro; T Meyer; P Imbach
Journal:  J Comput Aided Mol Des       Date:  2000-07       Impact factor: 3.686

10.  Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C-mediated signal transduction pathways by the staurosporine derivative CGP 41251.

Authors:  E Andrejauskas-Buchdunger; U Regenass
Journal:  Cancer Res       Date:  1992-10-01       Impact factor: 12.701

View more
  1 in total

1.  Drug design for ever, from hype to hope.

Authors:  G Seddon; V Lounnas; R McGuire; T van den Bergh; R P Bywater; L Oliveira; G Vriend
Journal:  J Comput Aided Mol Des       Date:  2012-01-18       Impact factor: 3.686

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.